Working with the team at Rubius has been a great experience. Their focus on strong English skills has allowed us to discuss projects efficiently and they are very accommodating when it comes to communicating at a time convenient to my company.
Rubius Company – YouTube
The Investor Relations website contains information about Rubius Therapeutics’s business for stockholders, potential investors, and financial analysts.
Rubius Therapeutics, Inc.: Private Company Information
2019-03-10 · Company Overview. Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius …
Rubius Therapeutics | LinkedIn
About us. Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to …
About Rubius – Rubius Company
The head office of the company is located in Tomsk, Siberia which is one of the significant world centers of IT industry. In Tomsk, there are 9 Universities, 15 Scientific Research Institutes, 6 business incubators and a special economic area of technical-innovation type.
Rubius Therapeutics Inc – Company Profile and News
Rubius Therapeutics, Inc. operates as a bio-technology company. The Company develops cellular therapies for the treatment of auto-immune, metabolic, and other diseases.
RUBIUS THERAPEUTICS, INC. (RUBY) IPO – NASDAQ.com
Join the Nasdaq Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!
Rubius Therapeutics, Inc. Secures $75 Million Loan Facility
2018-12-21 · Rubius Therapeutics, Inc. (RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today announced it …
Rubius Therapeutics – Official Site
Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines. With our deep scientific know-how and dedicated team, we are focused on making our vision a reality—creating life-changing cellular therapies for patients with rare enzyme deficiencies, cancer and autoimmune diseases.